AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04951063 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course.
Study NCT04951063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
Study NCT04951063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy
Description: Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
Study NCT05076370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Day 3
Description: CBD 1200mg
Study NCT06058455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEA3 Sexual Assault Resistance Intervention
Description: Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
Study NCT06058455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consent Workshop
Description: Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
Study NCT05626608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical ring stimulation
Description: Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
Study NCT05626608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation in directional mode
Description: Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
Study NCT05964166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph NMT Monitor
Description: TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
Study NCT06290505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.
Study NCT05717738 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: 8mg; p.o.; q.d.
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab Biosimilar IBI305 plus sintilimab
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Study NCT04941729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OR3O™ - Dual Mobility System
Description: OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
Study NCT04941729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
Study NCT05894148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab injection
Description: Group 1: 120mg Q4W，group 2: 200mg Q4W
Study NCT05894148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
Study NCT05458687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance
Description: * Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome.
Study NCT06382896 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This was an observational study
Study NCT06263738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Hyperthermia
Description: Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
Study NCT06263738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Plunge
Description: Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
Study NCT05685628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon dressing
Description: Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates.
Study NCT05685628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal dressing
Description: Use of ACTISORB® as a non-occlusive secondary dressing~CE marked medical device class IIb, without adhesive, consisting of a non-woven nylon envelope containing a layer of activated carbon. ACTISORB® can be applied as a primary or secondary dressing.
Study NCT06260748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Description: 250mg capsules
Study NCT06260748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chenodeoxycholic acid
Description: 250mg capsules
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab plus Atezolizumab
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: apatinib plus camrelizumab
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: 400mg; p.o. bid
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Donafenib
Description: 200mg; p.o. bid
Study NCT06260748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid Placebo
Description: Placebo to match
Study NCT01614288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: knee Arthroscopy
Description: Patient undergoes a knee arthroscopy and HTO
Study NCT01614288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No arthroscopy
Description: Patient undergoes an HTO without knee arthroscopy
Study NCT05717738 — intervention group
Intervention type: DRUG
Intervention: Regorafenib
Description: 160 mg; p.o.; q.d.
Study NCT04579380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg orally twice daily
Study NCT04579380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
Study NCT04579380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Study NCT05498766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
Study NCT05498766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
Study NCT05498766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur, Gimeracil and Oteracil Potassium
Description: Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
Study NCT06475196 — intervention group
Intervention type: DRUG
Intervention: Sintilimab (PD-1 inhibitor)
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
Study NCT04632290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STIMO-BSI system implantation
Description: Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
Study NCT05674084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary refill time
Description: CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and > 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
Study NCT05475769 — intervention group
Intervention type: DRUG
Intervention: Clinical evaluation
Description: Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
Study NCT05898646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06530901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multidimensional ultrasound of the inferior vena cava
Description: Cross-sectional parameters of the inferior vena cava include two-dimensional longitudinal diameter, cross-sectional length and short diameter, circumference, and cross-sectional area, as well as cross-sectional length and short diameter, circumference, and cross-sectional area in three-dimensional imaging
Study NCT06611631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid pulpotomy
Description: 1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown.
Study NCT06611631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mineral trioxide aggregate pulpotomy
Description: 1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown.
Study NCT06666855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117B Eye Drops
Description: Investigational Product: 0.002% DE-117B Eye Drops
Study NCT06666855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Active Control: 0.005% Latanoprost Eye Drops
Study NCT06667466 — intervention group
Intervention type: DEVICE
Intervention: Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention
Description: The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
Study NCT06667466 — intervention group
Intervention type: DEVICE
Intervention: Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention
Description: The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
Study NCT06671028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Lidocaine
Description: Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
Study NCT06671028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,5%
Description: Popliteal sciatic block using ropivacaine 0.5% 20 mL
Study NCT06672094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NeuroQ
Description: Two (2) capsules of NeuroQ taken once a day for 60 days.
Study NCT06672094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two (2) capsules of placebo taken once a day for 60 days.
Study NCT06671080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
Study NCT06671639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Xi Robotic Surgery System
Description: The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system.
Study NCT05898646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05898646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC
Study NCT05898646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Given SC
Study NCT06046222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-229
Description: Experimental
Study NCT06046222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT06115278 — intervention group
Intervention type: OTHER
Intervention: survey
Description: survey
Study NCT05931705 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire
Study NCT06023199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Voxelotor is administered orally at a dose of 1500mg daily.
Study NCT06672796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Toe Spread Out Exercise
Description: new resistance exercise phase in addition to the standard protocol
Study NCT06672796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toe Spread Out Exercise
Description: Standart protocol of toe spread out exercise
Study NCT05898646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT05898646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT05898646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05898646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05898646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study NCT04609280 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Description: Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
Study NCT05697679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.